GoodRx Holdings, Inc. (GDRX)
| Market Cap | 1.20B -23.0% |
| Revenue (ttm) | 785.23M -1.8% |
| Net Income | 16.25M -53.0% |
| EPS | 0.05 -46.8% |
| Shares Out | 341.15M |
| PE Ratio | 74.37 |
| Forward PE | 32.69 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,001,591 |
| Open | 3.500 |
| Previous Close | 3.510 |
| Day's Range | 3.500 - 3.595 |
| 52-Week Range | 1.770 - 5.810 |
| Beta | 1.58 |
| Analysts | Hold |
| Price Target | 4.03 (+14.16%) |
| Earnings Date | Aug 5, 2026 |
About GDRX
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscription programs and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. In ad... [Read more]
Financial Performance
In 2025, GoodRx Holdings's revenue was $796.85 million, an increase of 0.57% compared to the previous year's $792.32 million. Earnings were $30.44 million, an increase of 85.72%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for GDRX stock is "Hold." The 12-month stock price target is $4.03, which is an increase of 14.16% from the latest price.
News
GoodRx price target raised to $4 from $3 at Barclays
Barclays raised the firm’s price target on GoodRx (GDRX) to $4 from $3 and keeps an Underweight rating on the shares.
GoodRx price target raised to $3.75 from $2.50 at UBS
UBS raised the firm’s price target on GoodRx (GDRX) to $3.75 from $2.50 and keeps a Neutral rating on the shares.
GoodRx price target raised to $5 from $4 at TD Cowen
TD Cowen raised the firm’s price target on GoodRx (GDRX) to $5 from $4 and keeps a Buy rating on the shares. The firm updated its model following strong Q2…
GoodRx price target raised to $5 from $4 at Citi
Citi raised the firm’s price target on GoodRx (GDRX) to $5 from $4 and keeps a Buy rating on the shares. The firm updated its ratings and targets in the…
GoodRx price target raised to $4.50 from $3.50 at Raymond James
Raymond James analyst Parke Snure raised the firm’s price target on GoodRx (GDRX) to $4.50 from $3.50 and keeps an Outperform rating on the shares.
GoodRx price target raised to $4 from $3 at Morgan Stanley
Morgan Stanley raised the firm’s price target on GoodRx (GDRX) to $4 from $3 and keeps an Equal Weight rating on the shares.
GoodRx price target raised to $4 from $3.50 at Goldman Sachs
Goldman Sachs raised the firm’s price target on GoodRx (GDRX) to $4 from $3.50 and keeps a Neutral rating on the shares.
Push for 'COMPETITIVE CASH PRICING': GoodRx CEO on TrumpRx partnership
GoodRx CEO Wendy Barnes discusses the company's partnership with TrumpRx and efforts to lower prescription drug costs on ‘The Claman Countdown.'
GoodRx price target raised to $5 from $3.50 at Leerink
Leerink raised the firm’s price target on GoodRx (GDRX) to $5 from $3.50 and keeps an Outperform rating on the shares.
GoodRx and Oscar Health Tout Tech as Consumer Needs Change
The latest earnings from Oscar Health and GoodRx show both companies dealing with a changing customer base. The former company reported half-year earnings Thursday (Aug. 6) showing record profitabilit...
GoodRx Holdings Earnings Call Transcript: Q2 2026
Q2 2026 results exceeded expectations with strong growth in Pharma Direct (up 76% YoY) and subscriptions (up 39% YoY), prompting raised full-year revenue and EBITDA guidance. Strategic focus on scaling new offerings and deepening pharma partnerships is driving durable growth.
GoodRx Holdings Quarterly report: Q2 2026
GoodRx Holdings has published its Q2 2026 quarterly earnings report on August 6, 2026.
GoodRx Holdings Earnings release: Q2 2026
GoodRx Holdings released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
GoodRx Reports Second Quarter 2026 Results
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading platform for medication savings in the U.S., has released its f...
Citi adds ‘upside 30-day catalyst watch’ on GoodRx
Citi analyst Daniel Grosslight added an “upside 30-day catalyst watch” on GoodRx (GDRX) while keeping a Buy rating on the shares with a $4 price target GoodRx said it has…
GoodRx Announces Date for Second Quarter 2026 Earnings Release and Conference Call
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for prescription savings in the U.S., today announced it will release its ...
GoodRx Holdings Transcript: AGM 2026
The meeting covered board elections, auditor ratification, and executive compensation, with all proposals approved by shareholders. No questions were submitted during the Q&A session. Final voting results will be published in a Form 8-K filing.
GoodRx launches GoodRX Companion, a new subscription
GoodRx (GDRX) launched GoodRx Companion, a new $14.99-per-month subscription. “GoodRx Companion is an important step in our evolution toward building a broader subscription model built for the way con...
GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today launched GoodRx Companion, a new $14.99-per-month subscription that bring...
GoodRx price target raised to $4 from $3.50 at Citi
Citi raised the firm’s price target on GoodRx (GDRX) to $4 from $3.50 and keeps a Buy rating on the shares.
GoodRx price target raised to $4 from $3 at TD Cowen
TD Cowen analyst Charles Rhyee raised the firm’s price target on GoodRx (GDRX) to $4 from $3 and keeps a Buy rating on the shares. The firm said the company…
GoodRx price target raised to $3.50 from $2.50 at Goldman Sachs
Goldman Sachs analyst Eric Sheridan raised the firm’s price target on GoodRx (GDRX) to $3.50 from $2.50 and keeps a Neutral rating on the shares.
Big Pharma Runs Its Checkout Counter Through GoodRx
Out-of-pocket drug costs are rising for millions of Americans. Coverage gaps are widening.
GoodRx Holdings Earnings Call Transcript: Q1 2026
Q1 saw strong revenue and EBITDA growth, led by Pharma Direct's 82% year-over-year increase and robust subscription momentum. Full-year guidance was raised, with Pharma Direct expected to grow over 50% and subscriptions scaling, despite ongoing pressure on prescription transactions revenue.
GoodRx Holdings Quarterly report: Q1 2026
GoodRx Holdings has published its Q1 2026 quarterly earnings report on May 7, 2026.